Microbiome Disease Pipeline Outlook Report 2025: Key 140+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Microbiome Disease Pipeline Insights 2025" report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in Microbiome Disease pipeline landscape. It covers the Microbiome Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Microbiome Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Microbiome Disease Pipeline Outlook Report [https://www.delveinsight.com/sample-request/microbiome-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Microbiome Disease Pipeline Report

* In July 2025, Microbiome Health Sciences announced a study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 adjunctive to PPI therapy on heartburn-free days in subjects with GERD-related heartburn symptoms who self-report improvement while on sustained daily PPI therapy. Heartburn-free days will be determined by subject report specific to any of the three questions ("burning feeling behind the breastbone" and/or "pain behind your breastbone" and/or "heartburn"; Questions 1, 2 & 3 of the RESQ-eD).
* DelveInsight's Microbiome Disease pipeline report depicts a robust space with 140+ active players working to develop 180+ pipeline therapies for Microbiome Disease treatment.
* The leading Microbiome Disease Companies such as MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences Inc . and others.
* Promising Microbiome Disease Pipeline Therapies such as Omadacycline Injection, Imiquimod, Hydrocortisone Ointment, Clobetasol Ointment, Estrogen Cream, Altreno, Benzoyl peroxide , and others.

Learn how leading Microbiome Disease Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Microbiome Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/microbiome-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Microbiome Disease Emerging Drugs Profile

* MaaT 013: MaaT Pharma

MaaT013 is a standardized, high-richness, high-diversity Microbiome Ecosystem TherapyTM containing ButycoreTM (group of bacterial genera known to produce immuno-regulatory metabolites). It aims to restore the symbiotic relationship between the patient's functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). MaaT013 is an off-the-shelf, healthy-multi-donors-derived product intended for acute, hospital use. Currently the drug is in Phase III stage of development for the treatment of Graft-versus-host disease.

* QBKPN: Qu Biologics

QBKPN SSI, a first-in-class immune modulator designed to optimize immunity and barrier function in the lungs. The clinical trial is designed to assess QBKPN's effectiveness in restoring innate immunity, the prevention of serious morbidity and mortality from respiratory infections, including COVID-19 and its variants, and reduction in all-cause mortality. QBKPN SSI is designed to restore and enhance innate immune function, the body's first line of defense against all infections and other diseases such as cancer. Currently the drug is in Phase II stage of development for the treatment of immunodeficiency disorders.

* BMC128: Biomica Ltd.

BMC128 is a rationally-designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform powered by Evogene's MicroBoost AI platform. Developed as a Live Bacterial Product (LBP), BMC128 is an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbour specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes. Rationally-designed consortia are multi-strain products designed to restore diversity and specific functionality to a host's microbial community with individually selected, cultured bacteria. The drug is currently in Phase I stage of development for the treatment of patients with colorectal cancer.

* SER-155: Seres Therapeutics

SER-155 is a consortium of bacterial species selected using Seres' reverse translation discovery and development MbTx platform technologies. The design incorporates microbiome biomarker data from human clinical data and nonclinical human cell-based assays, and in vivo disease models. The SER-155 composition is designed to prevent and decrease the colonization and abundance of bacterial pathogens that can harbor antibiotic resistance and to enhance epithelial barrier integrity in the GI tract to both reduce the likelihood of pathogen translocation and decrease the incidence of bloodstream infections and GvHD. SER-155 has received FDA Fast Track Designation. The drug is currently in Phase I stage of development for the treatment of patients with Bacteraemia.

* MVT-201: Micro Viable Therapeutics

MVT-201, is an orally administered capsule generated under cGMP conditions representing the complete gut microbiota of a clinically validated healthy donor and will get into the clinical trials in 2024 for undisclosed targets. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is a unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding. This investment will enable to consolidate Microviable's growth and focus towards the therapeutics, while increasing their facilities and headcount. The drug is currently in Preclinical stage of development for the treatment of patients with infectious diseases.

The Microbiome Disease Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Microbiome Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Microbiome Disease Treatment.
* Microbiome Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Microbiome Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Microbiome Disease market.

From early-stage research to late-phase Microbiome Disease Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Microbiome Disease Treatment Drugs [https://www.delveinsight.com/sample-request/microbiome-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Microbiome Disease Companies

MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences Inc . and others.

Microbiome Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Microbiome Disease Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Stay updated with the latest Microbiome Disease Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Microbiome Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/microbiome-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Microbiome Disease Pipeline Report

* Coverage- Global
* Microbiome Disease Companies- MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc, Microbiotica, Enterome, Azitra, Vedanta Biosciences Inc . and others.
* Microbiome Disease Pipeline Therapies- Omadacycline Injection, Imiquimod, Hydrocortisone Ointment, Clobetasol Ointment, Estrogen Cream, Altreno, Benzoyl peroxide , and others.
* Microbiome Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Microbiome Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Microbiome Disease Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Microbiome Disease Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/microbiome-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Microbiome Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Microbiome Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* MaaT 013: MaaT Pharma
* Mid Stage Products (Phase II)
* QBKPN: Qu Biologics
* Early Stage Products (Phase I)
* BMC128: Biomica Ltd.
* Preclinical and Discovery Stage Products
* MVT-201: Micro Viable Therapeutics
* Inactive Products
* Microbiome Disease Key Companies
* Microbiome Disease Key Products
* Microbiome Disease- Unmet Needs
* Microbiome Disease- Market Drivers and Barriers
* Microbiome Disease- Future Perspectives and Conclusion
* Microbiome Disease Analyst Views
* Microbiome Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=microbiome-disease-pipeline-outlook-report-2025-key-140-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/microbiome-disease-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.